Cognition Therapeutics (CGTX): Pipeline, Trials & Analysis
A detailed profile of Cognition Therapeutics (CGTX) analyzing its pipeline, financials, and lead drug CT1812, a sigma-2 modulator for Alzheimer's and DLB.
Back to Articles
Articles tagged with “ct1812”